Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05945784
Other study ID # IRB: 000000001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 21, 2023
Est. completion date September 29, 2023

Study information

Verified date December 2023
Source Casa Colina Hospital and Centers for Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities. By examining various factors such as packaging design, product applicators, and ease of use, this research aims to identify barriers faced by individuals with upper extremity disabilities or visual deficits when using beauty products. The study seeks to provide insights and recommendations for improving the accessibility of beauty products, ultimately promoting inclusivity and enhancing the overall beauty experience for individuals with disabilities.


Description:

Individuals with upper extremity disabilities face unique challenges when it comes to using beauty products. These disabilities can include conditions such as limb loss, limited mobility, or dexterity impairments, which can significantly impact their ability to engage in self-care and beauty routines. The accessibility of beauty products is crucial to ensure that individuals with upper extremity disabilities have equal opportunities to participate in activities that promote self-expression and confidence. Research in the field of accessible design has highlighted the importance of inclusive product development across various industries, including cosmetics and personal care. However, limited attention has been given specifically to beauty products and their usability for individuals with upper extremity disabilities. To address this gap, studies are being conducted to assess the accessibility of beauty products and identify potential barriers and solutions. These studies typically examine factors such as packaging design, ergonomics of product applicators, ease of grip, and maneuverability. By understanding the specific challenges faced by individuals with upper extremity disabilities, researchers can propose modifications and design considerations that enhance accessibility.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date September 29, 2023
Est. primary completion date September 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: Individuals aged 18 years to 55 years. - Minimal to moderate upper extremity deficits, including but not limited to limited mobility or dexterity impairments. - Regular users beauty products. - Able to understand and communicate in the language of the study. Exclusion Criteria: - Individuals below 18 years of age or over the age of 55. - Individuals without upper extremity deficits or with severe upper extremity deficits that may affect the participant's ability to engage in study activities. - Participants who are not regular users of beauty products. - Inability to understand and communicate in the language of the study. - Any medical or psychological condition that may affect the participant's ability to provide informed consent or engage in the study activities safely. - Individuals who experience facial skin or eye irritation reported by subject or observed by evaluator at baseline visit - History of allergic reactions, and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc. - Immunocompromised subjects - Individuals who may experience changes in hormones, such as just those using oral contraception for less than three months before the screening visit or who have changed hormonal contraceptive methods within the three months before the Baseline visit or planning to modify hormonal contraception treatment within the duration of the study. - Known to be pregnant, lactating or planning to become pregnant within six months. Subjects who become pregnant during the study must inform the Principal Investigator immediately.

Study Design


Related Conditions & MeSH terms

  • Amyotrophic Lateral Sclerosis
  • Brain Injuries
  • Brain Injuries, Traumatic
  • Ehlers-Danlos Syndrome
  • Graves Disease
  • Guillain-Barre Syndrome
  • Hemorrhagic Stroke
  • Ischemic Stroke
  • Lupus Erythematosus
  • Motor Neuron Disease
  • Multiple Sclerosis
  • Muscular Dystrophies
  • Myasthenia Gravis
  • SCI - Spinal Cord Injury
  • Sclerosis
  • Spinal Cord Injuries
  • Stroke
  • Stroke (CVA) or TIA
  • Stroke Hemorrhagic
  • Stroke, Acute
  • Stroke, Ischemic
  • Syndrome
  • Traumatic Brain Injury
  • Wounds and Injuries

Intervention

Other:
Use of Rare Beauty makeup products
Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.

Locations

Country Name City State
United States Casa Colina Hospital and Centers for Healthcare Pomona California

Sponsors (1)

Lead Sponsor Collaborator
Casa Colina Hospital and Centers for Healthcare

Country where clinical trial is conducted

United States, 

References & Publications (3)

Chen L, Kim D, Park J, et al. A Review on Product Accessibility Evaluation Methods for People with Disabilities. Int J Ind Ergon. 2019;71:103-117. doi:10.1016/j.ergon.2018.11.007

Skelton H, Gill S, Al Zidjaly N, et al. Exploring the Accessibility of Beauty Products for Individuals with Mobility Disabilities. J Appl Cosmetol. 2020;38(3):65-72.

Smith A, Johnson R, Thompson A, et al. Enhancing Accessibility: Designing Inclusive Beauty Products for All Abilities. J Inclusive Design. 2021;1(2):89-102

Outcome

Type Measure Description Time frame Safety issue
Primary Likert Scale It is a validated self-reported instrument to assess packaging of the makeup. A few questions will focus on shape of the cap, length of the wand, shape of the doe foot, finish of the components, how it affects grip, and weight of the component/applicator. Possible scores range from 1 (strongly disagree) to 5 (strongly agree). Complete on Day 7
Primary Likert Scale It is a validated self-reported instrument to assess packaging of the makeup. A few questions will focus on shape of the cap, length of the wand, shape of the doe foot, finish of the components, how it affects grip, and weight of the component/applicator. Possible scores range from 1 (strongly disagree) to 5 (strongly agree). Complete on Day 14
Primary Pre-test Questionnaire Participants will complete questionnaires that assess their demographics, disability characteristics, and previous experiences with beauty products. At baseline
Primary Accessibility Evaluation Participants will evaluate the beauty products based on predefined criteria, including ease of grip, maneuverability, packaging design, and product applicators. They will document their experiences, challenges faced, and any suggestions for improvements. Possible scores range from 1 (strongly disagree) to 5 (strongly agree). Day 7, after use of beauty products
Primary Accessibility Evaluation Participants will evaluate the beauty products based on predefined criteria, including ease of grip, maneuverability, packaging design, and product applicators. They will document their experiences, challenges faced, and any suggestions for improvements. Possible scores range from 1 (strongly disagree) to 5 (strongly agree). Day 14, after use of beauty products at end of study
Primary Post-test Questionnaire Participants will assess changes in their perceptions and experiences with the beauty products. This will include questions about satisfaction, usability, and any perceived improvements in accessibility. Possible scores range from 1 (strongly disagree) to 5 (strongly agree). Day 14, after use of beauty products at end of study
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4